The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell ...

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

The immune system is central to identifying and eliminating foreign pathogens that enter the body. The innate and adaptive immune responses work together t | Immunology ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

In vivo CAR T cell generation is a pioneering immunotherapy approach that reprograms the immune system to fight cancer and ...

NORWOOD, MA, USA I June 25, 2025 I Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on ...